TBIO
Telesis Bio, Inc.
Set alert
- YTD
- -22.80%
- 1 year
- +221.67%
- Open
- 0.01155
- Prev close
- 0.0386
- Mkt cap
- 68.55K
- Vol
- 3
- Avg vol
- 281
- EPS
- -22.99
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 0.01155
- High
- 0.01155
- Forward P/E
- -0.07
- Beta
- 0.00
- Short ratio
- 0.42
- Inst. own
- 31.50%
- Dividend
- 0.00
- Ex-div date
- 50-d avg
- 2.47
- 200-d avg
- 4.85
- 1y target
- 0.00
Key statistics
- Market cap
- 2.27M
- Enterprise value
- 38.99M
- Trailing P/E
- 0.00
- Forward P/E
- -0.07
- PEG ratio
- 0.00
- Price / sales
- 0.15
- Price / book
- 0.00
- EPS (TTM)
- -30.42
- Beta
- 0.00
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- -292.59%
- Revenue (TTM)
- 15.57M
- Revenue growth
- -71.90%
- Free cash flow
- -12.21M
- Total cash
- 4.51M
- Total debt
- 10.45M
- Return on equity
- -176.11%
- Shares outstanding
- 1.77M
- Short % of float
- 7.31%
- 50-day average
- 2.47
- 200-day average
- 4.85
Analyst view
Consensus: buy
- Strong buy1
- Buy1
- Hold0
- Sell0
- Strong sell0
Next earnings
Consensus EPS estimate -6.58.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 7, 2024 | Sep 1, 2024 | 0.00 | -3.83 | — | — |
| Aug 7, 2024 | Jun 1, 2024 | 0.00 | -7.03 | — | — |
| May 9, 2024 | Mar 1, 2024 | 0.00 | -99.28 | — | — |
| Mar 28, 2024 | Dec 1, 2023 | -4.50 | -4.14 | +0.36 | +8.00% |
| Nov 13, 2023 | Sep 1, 2023 | -5.22 | -6.65 | -1.43 | -27.39% |
| Aug 10, 2023 | Jun 1, 2023 | -4.86 | -5.04 | -0.18 | -3.70% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Aug 10, 2023 | Keybanc | down | Overweight | Sector Weight |
| Nov 8, 2022 | Keybanc | main | — | Overweight |
| Mar 27, 2022 | Keybanc | main | — | Overweight |
| Jul 12, 2021 | Keybanc | init | — | Overweight |
| Jul 12, 2021 | Cowen & Co. | init | — | Outperform |
| Jul 12, 2021 | Jefferies | init | — | Buy |
About Telesis Bio, Inc.
Telesis Bio, Inc., a synthetic biology company, manufactures and sells synthetic biology instruments, reagents, and associated products and related services, primarily to pharmaceutical and academic laboratories worldwide. The company offers BioXp 3250 system and BioXp 9600 system that empower researchers to go from a digital DNA sequence to endpoint-ready synthetic deoxyribonucleic acid (DNA) and messenger ribonucleic acid (mRNA) with onboard next generation sequencing (NGS) library preparation; BioXp portal, an online portal that offers an intuitive guided workflow and design tools for building new DNA sequences and assembling them into vectors of choice, as well as mRNA constructs; and BioXp De Novo kits, which contains building blocks and reagents, including proprietary Gibson assembly branded reagents for specific synthetic biology workflow applications. It also provides BioXp Select kits that offers to use non-telesis bio DNA while using the BioXp system to perform synthetic biology workflow applications, such as cloning, mRNA generation from plasmid, and cell free amplification; BioXp Next Generation Sequencing kits, which contains reagents to go from DNA or RNA to a sequencer-ready library; Benchtop reagents that contains the reagents to proceed specific synthetic biology workflow on the benchtop using products generated on the BioXp system; and custom Gibson short oligo ligation assembly enzymatic DNA synthesis solutions, which is designed to construct synthetic DNA, RNA, and proteins for development of mRNA-based vaccines, diagnostics, therapeutics, and personalized medicines. The company serves its products to government institutions, contract research organizations, and synthetic biology companies. The company was formerly known as Codex DNA, Inc. and changed its name to Telesis Bio Inc. in November 2022. Telesis Bio, Inc. was incorporated in 2011 and is headquartered in San Diego, California.
- Sector
- Healthcare
- Industry
- Medical Devices
- Country
- United States
- Website
- telesisbio.com
News
- Telesis Bio and Beckman Coulter Life Sciences Collaborate to Revolutionize DNA and mRNA Synthesis
- Why Exicure Shares Are Trading Higher By Around 180%; Here Are 20 Stocks Moving Premarket
- Nasdaq Surges Over 200 Points; US Crude Oil Stocks Increase
- Crude Oil Surges 2.5%; Rentokil Initial Shares Plunge
- Why Dave & Buster's Shares Are Trading Higher By Around 13%; Here Are 20 Stocks Moving Premarket
- Telesis Bio Plans to Delist its Securities from The Nasdaq Stock Market
- Telesis Bio Reports Second Quarter and First Half 2024 Financial Results
- Telesis Bio Reports First Quarter 2024 Financial Results
- Telesis Bio Announces Reverse Stock Split
- 12 Health Care Stocks Moving In Wednesday's After-Market Session
Your note
Sign in to keep a note on TBIO — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| GOLUB STEVEN J | Director | Stock Award(Grant) | Jul 23, 2024 | 8,390 |
| HERREMA GREGORY J | Director | Stock Award(Grant) | Apr 30, 2024 | 184,677 |
| HLAVINKA SARAH E | Director | Stock Award(Grant) | Jul 23, 2024 | 8,390 |
| HODGES MICHAEL | Director | Stock Award(Grant) | Jul 23, 2024 | 8,390 |
| KRUEGER TODD | Director | Stock Award(Grant) | Jul 23, 2024 | 8,390 |
| NACHTSHEIM JAMI DOVER K | Director | Stock Award(Grant) | Apr 30, 2024 | 101,679 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Northpond Ventures, Llc | 32.87% | 9,844,130 | 15.55M | Jun 29, 2023 |
| Penn Capital Management Co., Inc. | 1.94% | 579,522 | 915.64K | Jun 29, 2023 |
| Vanguard Group Inc | 1.43% | 427,202 | 674.98K | Jun 29, 2023 |
| Penbrook Management LLC | 1.21% | 363,570 | 378.11K | Sep 29, 2023 |
| Millennium Management Llc | 0.84% | 251,670 | 397.64K | Jun 29, 2023 |
| Bridgeway Capital Management, Inc. | 0.39% | 117,000 | 184.86K | Jun 29, 2023 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 1.03% | 307,523 | 485.89K | Jun 29, 2023 |
| Bridgeway Funds Inc-Ultra Small Company Market Fund | 0.39% | 117,000 | 184.86K | Jun 29, 2023 |
| Vanguard Extended Market Index Fund | 0.37% | 110,770 | 175.02K | Jun 29, 2023 |
| Fidelity Extended Market Index Fund | 0.13% | 38,866 | 62.19K | May 30, 2023 |
| iShares Micro Cap ETF | 0.08% | 24,060 | 31.28K | Aug 30, 2023 |
| Fidelity Series Total Market Index Fund | 0.04% | 11,530 | 18.45K | May 30, 2023 |